HYDRALYTE_1170x120

Amneal and Impax create diversified pharmaceutical company

Print Friendly, PDF & Email
BRIDGEWATER, N.J. — Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. announced that they have completed their business combination to form Amneal Pharmaceuticals, Inc. As a diversified company with a robust generics business, Amneal is now the 5th largest generics business in the United States, with a growing, high-margin specialty franchise.

Shares of Impax  ceased trading on the NASDAQ stock exchange on May 4, 2018. Amneal has begun trading today on the New York Stock Exchange under the ticker “AMRX”. Pursuant to the business combination agreement, each share of Impax common stock was converted into the right to receive one share of Amneal Class A common stock.

“We are very excited for the future of Amneal, and strongly believe that with our team, differentiated product portfolio, extensive R&D and manufacturing infrastructure and expertise, Amneal is well positioned to become an industry leader,” said Chirag Patel and Chintu Patel, co-founders and co-chairmen of Amneal. “We are very proud of the Company we have built and look forward to Amneal’s continued success under Rob Stewart’s leadership.”

Robert Stewart, president and chief Executive officer of Amneal, said, “As we enter our next stage of growth, we look forward to implementing our integration plans and quickly starting to realize the many benefits of this combination. We will promptly begin to leverage our enhanced product portfolio to fuel organic growth while capturing numerous synergies to unlock value and generate strong cash flow to support the rapid repayment of debt and further investment in growth opportunities.”

The company expects to benefit from its expanded product portfolio, differentiated pipeline and cost-efficient global manufacturing and development capabilities in nearly all dosage forms. Amneal expects to generate annual double-digit revenue and adjusted EPS growth and to achieve annual cost synergies of approximately $200 million within three years.

“This is a truly transformative combination that firmly establishes Amneal as an industry leader, with high-value generic product pipelines and a growing specialty business,” said Paul Bisaro, executive chairman of Amneal. “With our combined resources, we are well-positioned to execute our plans to bring high-quality, affordable medicines to patients and generate long-term returns for our shareholders.”


EMC_728x90

INNOV_728x90_8-1-17

Comments are closed.